Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071406 | 0.87 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL5767134 | 0.78 | FGFR4 (0.59) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL18897200 | 0.78 | FGFR4 (0.54) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL29388619 | 0.78 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL22532554 | 0.78 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071565 | 0.74 | FGFR4 (0.55) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL22532368 | 0.74 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL28656646 | 0.74 | FGFR4 (0.50) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL15412943 | 0.72 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL21166431 | 0.72 | FGFR1 (0.60) | FGFR4FGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885FGFR1 3322/4885FGFR2 1531/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885FGFR1 3322/4885FGFR2 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.